相关实验视频

Updated: Sep 10, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

597

使用Nadofaragene Firadenovec重新诱导的结果

Bogdana Schmidt1,2, Joshua J Horns3, Mark D Tyson4

  • 1Huntsman Cancer Institute, Salt Lake City, Utah.

The Journal of urology
|August 25, 2025
PubMed
概括

No abstract available in PubMed .

关键词:
膀的癌症免疫瘤学在体内注射

更多相关视频

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K
Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition
11:45

Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition

Published on: November 14, 2013

12.3K

相关实验视频

Last Updated: Sep 10, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

597
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K
Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition
11:45

Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition

Published on: November 14, 2013

12.3K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
JoVE
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
Jove
Visualize
联系我们